Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Release Can Change the CTCL and Oral Mucositis Treatment Landscape
Miami Beach, Florida--(Newsfile Corp. - October 22, 2019) - There are two things that developing biotechs need for success. First, they need a good drug. Second, they need cash to fund clinical trials. Soligenix has both (NASDAQ: SNGX). Combined, the two may offer Soligenix investors a near-term opportunity to enjoy the rewards of both an FDA approval and the subsequent commercial launch of at least two promising drugs, SGX301 and SGX942, each targeting unmet medical needs. And, perhaps the...
2019-10-22 8:48 AM EDT
Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer
Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ: SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head and neck cancer, an unmet medical need. And, as the release date approaches, investors may be looking for any clue they can get as to how the drug is performing. That clue, incidentally, may have been provided by the independent Data Monitoring Committee (DMC),...
2019-10-03 8:16 AM EDT